[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611463":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":33,"locations":33,"responsibleParty":34,"collaborators":33,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":42,"eligibilityCriteria":43,"healthyVolunteers":38,"sex":44,"minAge":45,"maxAge":46,"enrollmentInfo":47,"targetDuration":33,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":60,"whyStopped":33,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":33},{"fullName":5,"class":6},"The Third Xiangya Hospital of Central South University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"hemodynamics-based individualized antihypertensive therapy","EXPERIMENTAL","The antihypertensive strategy is individualized according to the patient's hemodynamic indices:\n\nHigh-resistance type: Amlodipine Besylate Tablets 5mg, once daily, orally. High cardiac output type: Metoprolol Sustained-Release Tablets 47.5mg, once daily, orally.\n\nHypervolemic type: Indapamide Tablets 2.5mg, once daily, orally.",[13],"Drug: hemodynamics-based individualized antihypertensive therapy",{"label":15,"type":16,"description":17,"interventionNames":18},"guideline-based conventional therapy","ACTIVE_COMPARATOR","Developing a monotherapy antihypertensive treatment plan for participants based on the 2024 Chinese hypertension guidelines",[19],"Drug: guideline-based conventional treatment",[21,27],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","The antihypertensive strategy is individualized according to the patient's hemodynamic indices:\n\nHigh-resistance type: Amlodipine Besylate Tablets 5mg, once daily, orally. High cardiac output type: Metoprolol Sustained-Release Tablets 47.5mg, once daily, orally.\n\nHypervolemic type: Indapamide Tablets 2.5mg, once daily, orally. Participants will take the therapy for 8 weeks.",[9],[26],"individualized therapy",{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"guideline-based conventional treatment","Developing a monotherapy antihypertensive treatment plan for participants based on the 2024 Chinese hypertension guidelines.\n\nParticipants will take this treatment for 8 weeks.",[15],[32],"conventional treatment",null,{"type":35,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR","100611463","phase-4-antihypertensive-drug-selection-based-on-hemodynamic-phenotypes-100611463",false,"NCT07240909","Antihypertensive Drug Selection Based on Hemodynamic Phenotypes","A Multicenter, Randomized, PROBE Trial on Antihypertensive Drug Selection Based on Hemodynamic Phenotypes Defined by Bioelectrical Impedance Analysis","HEMOPHENO","Inclusion Criteria:\n\n1. Aged ≥30 and \\\u003C80 years, regardless of gender;\n2. Confirmed diagnosis of hypertension meeting the criteria outlined in the 2024 Chinese Hypertension Guidelines: office blood pressure ≥140\u002F90 mmHg and home blood pressure ≥135\u002F85 mmHg;\n3. Mild to moderate hypertension, with office blood pressure ranging from 140-179\u002F90-109 mmHg;\n4. No prior use of antihypertensive medications;\n5. Voluntary participation in the study with written informed consent obtained.\n\nExclusion Criteria:\n\n1. Diagnosed or highly suspected secondary hypertension;\n2. Classified as mixed type according to hemodynamic typing;\n3. Allergy to the intended antihypertensive medications;\n4. Dysphagia;\n5. Pregnant or lactating women;\n6. Potential pregnancy plans during the trial period;\n7. Uncorrected electrolyte disturbances;\n8. Severe organ dysfunction;\n9. Comorbid conditions leading to inaccurate blood pressure measurement;\n10. Comorbid conditions or states unsuitable for noninvasive hemodynamic measurement via bioelectrical impedance;\n11. Comorbid conditions contraindicating or requiring caution with trial medications;\n12. Comorbid conditions affecting the absorption, distribution, metabolism, or excretion of trial drugs;\n13. Concurrent or planned use of medications contraindicated or requiring caution with trial drugs;\n14. Concurrent or planned use of medications interfering with trial outcomes;\n15. Clinician's assessment deems the patient unsuitable for the trial's antihypertensive regimen;\n16. Current participation in other clinical studies that may interfere with the conduct of this trial.","ALL","30 Years","80 Years",{"count":48,"type":49},240,"ESTIMATED","INTERVENTIONAL",[52],"PHASE4","The goal of this clinical trial is to explore the clinical efficacy and safety of individualized antihypertensive medication guided by hemodynamic phenotyping. The main questions it aims to answer are:\n\n1. Does hemodynamics-based individualized antihypertensive therapy achieve better blood pressure control compared to guideline-based conventional therapy?\n2. Does hemodynamics-based individualized therapy have comparable safety to guideline-based conventional treatment? Researchers will compare hemodynamics-based individualized antihypertensive therapy to guideline-based conventional treatment to see if the former is better than the latter.\n\nParticipants will:\n\n1. Take hemodynamics-based individualized antihypertensive therapy or guideline-based conventional treatment every day for 8 weeks\n2. Visit the clinic once every 4 weeks for checkups and tests\n3. Keep a diary of their symptoms and any treatment",[55],"Hypertension",[57,58,59],"hypertension","anti-hypertensive therapy","Hemodynamics","NOT_YET_RECRUITING","2025-11-16",{"date":63,"type":64},"2025-11-21","ACTUAL",{"date":66,"type":49},"2026-01",{"date":68,"type":49},"2026-12",{"name":5,"class":6}]